Publications by authors named "Kadzuhiro Kitakawa"
Article Synopsis
- A case study highlights the successful use of high-dose intravenous immunoglobulin (IVIg) treatment in a patient with severe COVID-19, leading to significant improvement in lung inflammation despite prior clinical deterioration.
- The deterioration was attributed to the reactivation of proinflammatory factors (like tumor necrosis factor-α and interleukin-6), not just the viral presence.
- IVIg may help manage severe COVID-19 by suppressing the immune response and inhibiting harmful cytokines, potentially countering the cytokine storm associated with SARS-CoV-2 infection.
Background: Human parechovirus type 3 (HPeV-3) is known to cause cold-like symptoms, diarrhea, or severe infections such as sepsis in infants and children. In adults, HPeV-3 infection is rarely diagnosed because the symptoms are generally mild and self-limiting; however, this infection has been linked to epidemic myalgia, regardless of the presence of underlying diseases, immunosuppression, or sex.
Case Presentation: We describe an adult case of severe systemic myalgia and orchiodynia after infection with HPeV-3, which was transmitted from the child of the patient.